Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Anastrozole is a selective aromatase inhibitor (estrogen synthetase), which inhibits the secretion of estrogen. Indicated in the treatment of breast cancer in postmenopause. Oral administration once a day for prolonged periods.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (low molecular weight, low protein binding and prolonged half-life) enables transfer to breastmilk in amounts which could be significant.
During cancer treatment, breastfeeding must be interrupted due to potentially serious side effects for the infant.
Pharmacokinetics show that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ it is 94%, after 5 T½, 96.9%, after 6 T½, 98.4% and after 7 T½ it is 99%. From 7 T½ the plasma concentrations of the drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period before breastfeeding again. (Anderson 2016)
According to this data, the interruption of breastfeeding would be for a period of between 10.4 days (5 T½) to 14.6 days (7 T½) after the administration of the last dose, which coincides with the estimates of other authors. (Hale)
Its long elimination half-life and its daily administration over many months make it impossible to continue breastfeeding.
Accidental intake of a single dose does not require an interruption of breastfeeding. However, treatment should not be continued. (Schaefer 2015)
See below the information of this related product: